Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 6/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | BRS3 | P32247 | 1/20 | 0.37 |
| ▸ | KDM6B | O15054 | 1/20 | 0.37 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18522430 | 0.84 | NAMPT (0.50) | CYP17A1NAMPTRAB9ABRS3KDM4C | |
| SCHEMBL6034950 | 0.78 | CYP17A1 (0.44) | CYP17A1NAMPTBCHERAB9ACYP3A4 | |
| SCHEMBL5746768 | 0.77 | CYP17A1 (0.46) | CYP17A1NAMPTRAB9ABRS3KDM6B | |
| SCHEMBL28994432 | 0.76 | TERT (0.48) | TERTBCHEKDM6BKDM4DKDM4C | |
| SCHEMBL16010923 | 0.75 | HDAC3 (0.47) | CYP3A4 | |
| SCHEMBL23674773 | 0.74 | CYP17A1 (0.48) | CYP17A1NAMPTRAB9ABRS3 | |
| SCHEMBL30601022 | 0.74 | CYP17A1 (0.48) | CYP17A1NAMPTRAB9ACYP3A4KDM6B | |
| SCHEMBL12018154 | 0.74 | CYP17A1 (0.48) | CYP17A1NAMPTRAB9ACYP3A4KDM6B | |
| SCHEMBL3666785 | 0.74 | NAMPT (0.48) | CYP17A1NAMPTRAB9ABRS3 | |
| SCHEMBL555073 | 0.74 | NAMPT (0.48) | CYP17A1NAMPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190891-A1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-06-13 | — | — | US | disclosed |
| EP-4182323-B1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARM SPA (IT) | 2024-04-24 | — | — | EP | disclosed |
| CN-116075307-A | Pyridooxazine amino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2023-05-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190891-A1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | TGFBR1, ACVR1, ALK | TERT 3405/4885CYP17A1 2244/4885NAMPT 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.